GLP-1 Modulation with Mitochondrial Energy Synergy
Mechanistic Synergy for Research:
- Semaglutide, a GLP-1 analog, improves insulin sensitivity, suppresses glucagon, and delays gastric emptying in metabolic models.
- NAD⁺ supports mitochondrial respiration, ATP synthesis, and SIRT1 activation, which are all critical for maintaining metabolic flexibility and insulin signaling.
Combined Benefits:
- NAD⁺ enhances Semaglutide-induced insulin sensitivity by increasing AMPK and SIRT1 pathways.
- Semaglutide reduces metabolic inflammation and ROS—effects further supported by NAD⁺’s role in DNA repair and oxidative resilience.
Use Cases:
Obesity research, insulin resistance models, mitochondrial energetics studies.
